It's no secret that brand-name drugs in the U.S. are much more expensive than they are abroad. In the spirit of fairness, the ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The complete response (CR) rate at 1 month improved from 25% with single-fraction conformal 3D RT (3D-CRT) to 37% with SBRT, ...

The median age at symptom onset in the cohort was 55 years, ranging from 16 to 81 years. Data from patients’ initial ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve ...

Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first ...

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Bristol-Myers Squibb Co. prevailed against investor allegations it misled them about a payout tied to Food and Drug ...

President Donald Trump is attempting to slash drug prices for Americans by more closely aligning their costs to lower prices ...